Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
- Sponsor:
- Janssen
- Sponsor Study ID:
- 68284528MMY4006 EAP
- CTO #:
- 104061
- NCT Number:
- NCT05346835
- Phase:
- N/A
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Multiple Myeloma
- Study Objectives:
- EAP protocol to administer Out-of-Specification (OOS) Ciltacabtagene autoleucel (cilta-cel) to patients with serious/life-threatening Multiple Myeloma
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Caveney, Joseph, at caveney@musc.edu
- Study Coordinator, Mendiola, Hannah, at mendiola@musc.edu
Trial opened at the following institutions:
Medical University of South Carolina